Cooper Companies (NASDAQ:COO) Price Target Raised to $101.00 at Needham & Company LLC

Cooper Companies (NASDAQ:COO) had its target price hoisted by Needham & Company LLC from $99.00 to $101.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical device company’s stock.

Several other brokerages have also recently weighed in on COO. Rothschild & Co Redburn cut shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 price target for the company. in a research note on Wednesday. William Blair upgraded shares of Cooper Companies to a “strong-buy” rating in a report on Friday, January 30th. Stifel Nicolaus set a $95.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a research report on Friday, December 5th. The Goldman Sachs Group reiterated a “sell” rating and issued a $73.00 price target on shares of Cooper Companies in a research note on Friday, January 9th. Finally, Barclays set a $98.00 price target on shares of Cooper Companies and gave the stock an “overweight” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

Cooper Companies Stock Down 4.6%

Shares of Cooper Companies stock traded down $3.65 during trading on Friday, reaching $76.55. The stock had a trading volume of 5,297,517 shares, compared to its average volume of 1,770,237. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $14.94 billion, a price-to-earnings ratio of 37.90, a P/E/G ratio of 2.29 and a beta of 1.02. The stock has a fifty day moving average price of $82.11 and a two-hundred day moving average price of $75.97. Cooper Companies has a 52 week low of $61.78 and a 52 week high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.07. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Cooper Companies had a return on equity of 10.36% and a net margin of 9.67%.Cooper Companies’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the company earned $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Maria Rivas bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the completion of the acquisition, the director owned 11,141 shares in the company, valued at approximately $915,010.33. This represents a 9.86% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Holly R. Sheffield purchased 1,230 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were purchased at an average cost of $80.75 per share, for a total transaction of $99,322.50. Following the completion of the transaction, the insider directly owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. This represents a 3.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 16,014 shares of company stock worth $1,304,416 in the last quarter. 2.08% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of COO. River Road Asset Management LLC raised its holdings in shares of Cooper Companies by 1.0% in the 4th quarter. River Road Asset Management LLC now owns 1,582,867 shares of the medical device company’s stock valued at $129,732,000 after purchasing an additional 16,103 shares during the period. Kera Capital Partners Inc. acquired a new stake in Cooper Companies in the 4th quarter valued at about $216,000. Axxcess Wealth Management LLC grew its holdings in Cooper Companies by 37.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 9,980 shares of the medical device company’s stock worth $818,000 after purchasing an additional 2,698 shares during the period. Corient Private Wealth LLC grew its holdings in Cooper Companies by 17.0% during the fourth quarter. Corient Private Wealth LLC now owns 25,699 shares of the medical device company’s stock worth $2,106,000 after purchasing an additional 3,738 shares during the period. Finally, Alberta Investment Management Corp acquired a new position in Cooper Companies during the fourth quarter worth approximately $1,582,000. Institutional investors own 24.39% of the company’s stock.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free?cash?flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer?term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell?side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above?average financial growth and attractive style scores, which may keep the stock on growth?oriented portfolios but don’t guarantee near?term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact?lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in?line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near?term recovery in core vision that can limit upside until clearer top?line improvement is visible. Read More.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.